Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Stepping Into Diagnostics, Pens Biomarker Collaboration With Mayo Clinic

NEW YORK, Dec. 7 (GenomeWeb News) - Invitrogen and the Mayo Clinic will co-develop diagnostic biomarkers and the technologies to detect them, the two organizations said yesterday.


The aim of the collaboration---which marks the first time Invitrogen has stepped directly into the field of diagnostics--is to develop new diagnostic and prognostic tests for cancer and general laboratory medicine.


In the deal, Invitrogen will provide research tools, which include human protein microarrays, engineered cell lines, cell-based assays, and cloning and expression technologies. The Mayo Clinic will contribute patient samples and expertise in diagnostic assays. Invitrogen can license technologies resulting from the collaboration either exclusively or non-exclusively, in exchange for funding several biomarker research programs at Mayo.

"Our objective with this agreement is to generate new enabling technologies for doctors, patients and the larger health-care community," Invitrogen CEO Greg Lucier said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.